Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.64 |
| ▸ | TSHR | P16473 | 2/20 | 0.64 |
| ▸ | ATM | Q13315 | 1/20 | 0.64 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 7/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.46 |
| ▸ | HSPB1 | P04792 | 2/20 | 0.44 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13735059 | 0.85 | MAPT (0.56) | TDP1TSHRATMPDE7AMAPT | |
| SCHEMBL537892 | 0.83 | TDP1 (0.64) | TDP1TSHRATMPDE7AMAPT | |
| Fluoride SCHEMBL27394412 | 0.82 | TDP1 (0.62) | TDP1TSHRATMPDE7AMAPT | |
| SCHEMBL1373865 | 0.81 | HSPB1 (0.57) | TDP1TSHRATMPDE7AMAPT | |
| SCHEMBL5858703 | 0.81 | PDE7A (0.56) | TDP1TSHRATMPDE7AMAPT | |
| SCHEMBL216553 | 0.80 | TDP1 (0.72) | TDP1TSHRATMPDE7AALDH1A1 | |
| SCHEMBL29745239 | 0.80 | TDP1 (0.72) | TDP1TSHRATMPDE7AALDH1A1 | |
| SCHEMBL7744242 | 0.79 | MAPK1 (0.75) | TDP1TSHRATMMAPTALDH1A1 | |
| SCHEMBL3973537 | 0.78 | MAPT (0.69) | TDP1TSHRMAPTALDH1A1LMNA | |
| SCHEMBL57112 | 0.78 | TDP1 (1.00) | TDP1TSHRATMPDE7AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 923 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118702085-A | Method for regulating specific surface area of carbon material | 三明学院 | 2024-09-27 | — | — | CN | claimed |
| CN-107935858-B | Preparation method of 5-fluoro-2-nitrophenol | 利尔化学股份有限公司 | 2020-09-08 | — | — | CN | claimed |
| CN-111362867-A | Mobile terminal, shell assembly, electrochromic material and preparation method thereof | 宁波祢若电子科技有限公司 | 2020-07-03 | — | — | CN | claimed |
| CN-104407066-B | A kind of retigabine has the analysis method of related substance | 安徽万邦医药科技有限公司 | 2016-09-21 | — | — | CN | claimed |
| CN-104407066-A | Analysis method of retigabine related substances | ANHUI WANBANG MEDICAL TECHNOLOGY CO LTD | 2015-03-11 | — | — | CN | claimed |
| US-8222413-B2 | Methods for synthesizing heterocyclic compounds | NOVARTIS AG (US) | 2012-07-17 | — | — | US | claimed |
| EP-1888556-A1 | METHODS FOR SYNTHESIZING HETEROCYCLIC COMPOUNDS | Novartis Pharma AG (CH) | 2008-02-20 | — | — | EP | claimed |
| WO-2006125130-A1 | METHODS FOR SYNTHESIZING HETEROCYCLIC COMPOUNDS | NOVARTIS AG (CH) | 2006-11-23 | — | — | WO | claimed |
| EP-3364967-B1 | FERROPORTIN INHIBITORS | VIFOR INT AG (CH) | 2026-05-20 | — | — | EP | disclosed |
| EP-4741395-A1 | NOVEL COMPOUND SENSITIVE TO NITROGEN MONOXIDE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Omniamed Co. Ltd (KR) | 2026-05-13 | — | — | EP | disclosed |
| US-20260124205-A1 | MODULATORS OF BETA CATENIN AND USES THEREOF | DEWPOINT THERAPEUTICS INC (US) | 2026-05-07 | — | — | US | disclosed |
| EP-4736860-A2 | POLYCYCLIC COMPOUNDS FOR INHIBITING RNA HELICASE DHX33 AND USE THEREOF | Shenzhen Keye Life Technologies, Co., Ltd. (CN) | 2026-05-06 | — | — | EP | disclosed |
| WO-2026090104-A1 | MODULATORS OF BETA CATENIN AND USES THEREOF | DEWPOINT THERAPEUTICS, INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| US-12589156-B2 | Benzimidazole and benzimidazolone based protac compounds for the targeted degradation of leucine rich repeat kinase 2 (LRRK2) | ARVINAS OPERATIONS, INC. (US) | 2026-03-31 | — | — | US | disclosed |
| US-4264913-A | Electric discharge recording method and material with non-recording layer | SEKISUI KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1981-04-28 | — | — | US | disclosed |
| US-4185018-A | Process for producing benzofurazan-1-oxides | CIBA-GEIGY CORPORATION (US) | 1980-01-22 | — | — | US | disclosed |
| US-4163075-A | RESIN, METAL POWDER | SEKISUI KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1979-07-31 | — | — | US | disclosed |
| EP-0000121-A1 | 6-(1-Piperazinyl)-quinoxaline, process for its preparation and pharmaceutical compositions thereof | MERCK & CO. INC. (US) | 1979-01-10 | — | — | EP | disclosed |
| US-4091101-A | ANORECTIC AGENTS | MERCK & CO., INC. (US) | 1978-05-23 | — | — | US | disclosed |
| US-3957860-A | SULFAMIC ACID | CIBA-GEIGY AG (CH) | 1976-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260124205-A1 | MODULATORS OF BETA CATENIN AND USES THEREOF | CTNNB1, CTNNA1, CTNND1 | TDP1 3162/4885TSHR 2957/4885ATM 4266/4885 |
| US-12589156-B2 | Benzimidazole and benzimidazolone based protac compounds for the targeted degradation of leucine rich repeat kinase 2 (LRRK2) | LRRK2, SNCA, PARK7 | TDP1 3310/4885TSHR 3129/4885ATM 246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.